Refresh your memory of 4 CGM systems that received FDA-approval in 2018. Each one offers innovative features to help enhance diabetes care.
In 2018, the FDA issued approvals for several continuous glucose monitors (CGMs), and an expanded indication for a closed-loop artificial pancreas system. Since then, these systems have been rolled out and are currently being marketed in the US. This short slideshow offers compact summaries on 4 of these products which all offer innovative features like extended sensor wear-time, elimination of daily finger stick calibration, and integration with Siri and Google Fit apps.
Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?
May 8th 2013The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?